XML 44 R29.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Earnings (Loss) per Share | 12 Months Ended
--- | ---
Dec. 31, 2018
Earnings (Loss) per Share | NOTE 21—EARNINGS (LOSS) PER SHARE: The net income attributable to Teva and the weighted average number of ordinary shares used in computation of basic and diluted earnings per share for the years ended December 31, 2018, 2017 and 2016 are as follows:
|  | 2018 |  |  | 2017 |  |  | 2016 |
|  | (U.S. $ in millions, except share data) |
Net income (loss) used for the computation of diluted earnings per share |  | $ | (2,399 | ) |  | $ | (16,525 | ) |  | $ | 68 |
Weighted average number of shares used in the computation of basic earnings per share |  |  | 1,021 |  |  |  | 1,016 |  |  |  | 955 |
Add: |  |  |  |  |  |  |  |  |  |  |  |
Additional shares from the assumed exercise of employee stock options and unvested RSUs |  |  | — |  |  |  | — |  |  |  | 3 |
Weighted average number of additional shares issued upon the assumed conversion of convertible senior debentures |  |  | — |  |  |  | — |  |  |  | 3 |
Weighted average number of shares used in the computation of diluted earnings per share |  |  | 1,021 |  |  |  | 1,016 |  |  |  | 961 |
Basic earnings and loss per share are computed by dividing net results attributable to Teva’s ordinary shareholders by the weighted average number of ordinary shares outstanding (including fully vested restricted share units (“RSUs”)) during the period, net of treasury shares. In computing dilutive loss per share for the years ended December 31, 2018 and 2017, no account was taken of the potential dilution of the assumed exercise of employee stock options, RSUs and PSUs, amounting to 51 million and 38 million weighted average shares, respectively, and convertible senior debentures, since they had an anti-dilutive effect on earnings per share. Diluted earnings per share for the year ended 2016, take into account the potential dilution that could occur upon the exercise of options and non-vested RSUs granted under employee stock compensation plans, amounting to 4 million weighted average shares, using the treasury stock method since they had a dilutive effect on earnings per share. Additionally, in computing dilutive earnings per share for the period between January 1, 2018 and December 17, 2018 and for the years ended December 31, 2017 and 2016, no account was taken of the potential dilution of the mandatory convertible preferred shares amounting to 74 million, 59 million and 59 million weighted average shares, respectively, since they had an anti-dilutive effect on earnings (loss) per share. On December 17, 2018, the mandatory convertible preferred shares automatically converted into ordinary shares at a ratio of 1 mandatory convertible preferred share to 16 ADSs, and all of the accumulated and unpaid dividends on the mandatory convertible preferred shares were paid in ADSs, at a ratio of 3.0262 ADSs per mandatory convertible preferred share, all in accordance with the conversion mechanism set forth in the terms of the mandatory convertible preferred shares. As a result of this conversion, Teva issued 70.6 million ADSs.

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration